PMV PHARMACEUTICALS INC (PMVP) Fundamental Analysis & Valuation

NASDAQ:PMVP • US69353Y1038

Current stock price

1.38 USD
-0.03 (-2.13%)
Last:

This PMVP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. PMVP Profitability Analysis

1.1 Basic Checks

  • PMVP had negative earnings in the past year.
  • In the past year PMVP has reported a negative cash flow from operations.
  • In the past 5 years PMVP always reported negative net income.
  • In the past 5 years PMVP always reported negative operating cash flow.
PMVP Yearly Net Income VS EBIT VS OCF VS FCFPMVP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M

1.2 Ratios

  • With a Return On Assets value of -66.70%, PMVP is not doing good in the industry: 63.18% of the companies in the same industry are doing better.
  • PMVP has a Return On Equity (-74.24%) which is in line with its industry peers.
Industry RankSector Rank
ROA -66.7%
ROE -74.24%
ROIC N/A
ROA(3y)-41.58%
ROA(5y)-33.86%
ROE(3y)-46.05%
ROE(5y)-37.34%
ROIC(3y)N/A
ROIC(5y)N/A
PMVP Yearly ROA, ROE, ROICPMVP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for PMVP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PMVP Yearly Profit, Operating, Gross MarginsPMVP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. PMVP Health Analysis

2.1 Basic Checks

  • PMVP has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, PMVP has more shares outstanding
  • There is no outstanding debt for PMVP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PMVP Yearly Shares OutstandingPMVP Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
PMVP Yearly Total Debt VS Total AssetsPMVP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -2.93, we must say that PMVP is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -2.93, PMVP is in line with its industry, outperforming 46.12% of the companies in the same industry.
  • There is no outstanding debt for PMVP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.93
ROIC/WACCN/A
WACCN/A
PMVP Yearly LT Debt VS Equity VS FCFPMVP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • PMVP has a Current Ratio of 10.09. This indicates that PMVP is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of PMVP (10.09) is better than 79.46% of its industry peers.
  • PMVP has a Quick Ratio of 10.09. This indicates that PMVP is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 10.09, PMVP is doing good in the industry, outperforming 79.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.09
Quick Ratio 10.09
PMVP Yearly Current Assets VS Current LiabilitesPMVP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. PMVP Growth Analysis

3.1 Past

  • PMVP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.70%.
EPS 1Y (TTM)-30.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, PMVP will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.18% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-7.48%
EPS Next 2Y9.81%
EPS Next 3Y10.14%
EPS Next 5Y16.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PMVP Yearly Revenue VS EstimatesPMVP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
PMVP Yearly EPS VS EstimatesPMVP Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. PMVP Valuation Analysis

4.1 Price/Earnings Ratio

  • PMVP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year PMVP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PMVP Price Earnings VS Forward Price EarningsPMVP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PMVP Per share dataPMVP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.81%
EPS Next 3Y10.14%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PMVP Dividend Analysis

5.1 Amount

  • No dividends for PMVP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PMVP Fundamentals: All Metrics, Ratios and Statistics

PMV PHARMACEUTICALS INC

NASDAQ:PMVP (4/16/2026, 1:49:32 PM)

1.38

-0.03 (-2.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06
Earnings (Next)05-08
Inst Owners61.01%
Inst Owner Change0%
Ins Owners3.29%
Ins Owner Change1.65%
Market Cap73.60M
Revenue(TTM)N/A
Net Income(TTM)-77.74M
Analysts85
Price Target7.75 (461.59%)
Short Float %3.03%
Short Ratio2.27
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.13%
Min EPS beat(2)2.57%
Max EPS beat(2)17.7%
EPS beat(4)3
Avg EPS beat(4)6.59%
Min EPS beat(4)-4.86%
Max EPS beat(4)17.7%
EPS beat(8)5
Avg EPS beat(8)14.99%
EPS beat(12)9
Avg EPS beat(12)16.51%
EPS beat(16)13
Avg EPS beat(16)13.65%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-1.86%
EPS NQ rev (3m)-23%
EPS NY rev (1m)-9.6%
EPS NY rev (3m)-9.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.7
P/tB 0.7
EV/EBITDA N/A
EPS(TTM)-1.49
EYN/A
EPS(NY)-1.6
Fwd EYN/A
FCF(TTM)-1.38
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS0
BVpS1.96
TBVpS1.96
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -66.7%
ROE -74.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-41.58%
ROA(5y)-33.86%
ROE(3y)-46.05%
ROE(5y)-37.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.8%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.09
Quick Ratio 10.09
Altman-Z -2.93
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)51.86%
Cap/Depr(5y)616.97%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.44%
EPS Next Y-7.48%
EPS Next 2Y9.81%
EPS Next 3Y10.14%
EPS Next 5Y16.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-34.73%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-41.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-43.48%
OCF growth 3YN/A
OCF growth 5YN/A

PMV PHARMACEUTICALS INC / PMVP Fundamental Analysis FAQ

What is the fundamental rating for PMVP stock?

ChartMill assigns a fundamental rating of 2 / 10 to PMVP.


Can you provide the valuation status for PMV PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to PMV PHARMACEUTICALS INC (PMVP). This can be considered as Overvalued.


Can you provide the profitability details for PMV PHARMACEUTICALS INC?

PMV PHARMACEUTICALS INC (PMVP) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for PMVP stock?

The Earnings per Share (EPS) of PMV PHARMACEUTICALS INC (PMVP) is expected to decline by -7.48% in the next year.